È£Èí±â ÈíÀԱ⠽ÃÀå : À¯Çüº°, Á¦Ç°º°, ¿ëµµº°, ÃÖÁ¾ »ç¿ëÀÚº°, Áö¿ªº°
Respiratory Inhalers Market, By Type, By Product, By Application, By End User, By Geography
»óǰÄÚµå : 1672813
¸®¼­Ä¡»ç : Coherent Market Insights
¹ßÇàÀÏ : 2025³â 02¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹®
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,500 £Ü 6,511,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 7,000 £Ü 10,128,000
PDF (Multi User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 7¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 10,000 £Ü 14,469,000
PDF (Enterprise User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼¼°èÀÇ È£Èí±â ÈíÀԱ⠽ÃÀåÀº 2025³â¿¡´Â 351¾ï ´Þ·¯·Î ÃßÁ¤µÇ°í, 2032³â¿¡´Â 528¾ï 1,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, 2025³âºÎÅÍ 2032³â±îÁö 6.0%ÀÇ º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR)·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù.

º¸°í ¹üÀ§ º¸°í¼­ ¼¼ºÎÁ¤º¸
±âÁØ ¿¬µµ 2024³â ½ÃÀå ±Ô¸ð(2025³â) 351¾ï ´Þ·¯
½ÇÀû µ¥ÀÌÅÍ 2020-2024³â ¿¹Ãø ±â°£ 2025-2032³â
¿¹Ãø ±â°£ CAGR(2025-2032³â) : 6.00% ±Ý¾× ¿¹Ãø(2032³â) 528¾ï 1,000¸¸ ´Þ·¯
±×¸². È£Èí±â ÈíÀÔ±â Áö¿ªº° ½ÃÀå Á¡À¯À²(%)(2025³â)
Respiratory Inhalers Market-IMG1

È£Èí±â ÈíÀÔ±â´Â õ½ÄÀ̳ª COPD¿Í °°Àº È£Èí±â ÁúȯÀ» Ä¡·áÇϱâ À§ÇÑ ¾à¹° Åõ¿©¿¡ »ç¿ëµÇ´Â ÀÇ·á±â±âÀÔ´Ï´Ù. À̵éÀº ÇÊ¿äÇÑ ¾çÀÇ ¾à¹°À» ÈíÀÔ¿¡ ÀÇÇØ ±âµµ¿¡ Á÷Á¢ °ø±ÞÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ȯ°æ ¿äÀÎÀ¸·Î ÀÎÇÑ È£Èí±â ÁúȯÀÇ À¯º´·ü Áõ°¡, ÀÌ·¯ÇÑ »óÅ¿¡ °É¸®±â ½¬¿î ³ëÀÎ Áõ°¡, ÈíÀÔ±â Ä¡·á¿¡ ´ëÇÑ ÀÇ½Ä Áõ°¡´Â ½ÃÀå ¼ºÀåÀ» °¡¼Ó½Ãų ¼ö ÀÖ½À´Ï´Ù. ÈíÀԱ⠾๰Àü´Þ ±â¼úÀÇ Áøº¸, ½º¸¶Æ® ÈíÀÔ±â ¹× µðÁöÅÐ ÈíÀÔ±âÀÇ °³¹ß, È¿À²¼ºÀ» Çâ»ó½ÃŲ ÄÞº¸ ÈíÀÔ±âÀÇ µµÀÔµµ ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀÌ µË´Ï´Ù. ±×·¯³ª, Ä¡·áºñ°¡ ³ô°í, Áö¹æ¿¡¼­´Â ÀÌ¿ëÇÒ ¼ö ¾ø´Â °ÍÀÌ, º¸±ÞÀÇ ¹æÇذ¡ µÉ °¡´É¼ºÀÌ ÀÖ½À´Ï´Ù.

½ÃÀå ¿ªÇÐ

¼¼°èÀÇ È£Èí±â ÈíÀԱ⠽ÃÀåÀÇ ¼ºÀåÀº ÁÖ·Î ¼¼°èÀÇ È£Èí±â ÁúȯÀÇ À¯º´·ü Áõ°¡¿¡ ±âÀÎÇÕ´Ï´Ù. õ½Ä°ú COPDÀÇ ¹ßº´·üÀº ¿À¿° ¼öÁØ Áõ°¡, ¶óÀÌÇÁ ½ºÅ¸ÀÏ µ¿ÇâÀÇ º¯È­, ³ëÈ­·Î ÀÎÇØ Áö³­ ¼ö½Ê³âµ¿¾È ±ØÀûÀ¸·Î Áõ°¡Çϰí ÀÖ½À´Ï´Ù. WHOÀÇ µ¥ÀÌÅÍ¿¡ µû¸£¸é ÇöÀç ¾à 3¾ï ¸íÀÌ Ãµ½Ä¿¡ ½Ã´Þ¸®°í 2¾ï ¸í ÀÌ»óÀÌ COPD¸¦ ¾Î°í ÀÖ½À´Ï´Ù. Á¶±â Áø´Ü°ú È¿°úÀûÀÎ ÈíÀÔ ¿ä¹ýÀ» ÀÌ¿ëÇÒ ¼ö ÀÖ°Ô µÊÀ¸·Î½á ÀÌ·¯ÇÑ Áúº´ÀÇ Ä¡·á Àü¸ÁÀÌ °³¼±µÇ¾ú½À´Ï´Ù. Àú¼Òµæ ±¹°¡¿¡¼­´Â ÀÎÁöµµ°¡ ³·°í ÀϺΠ±¹°¡¿¡¼­´Â ºê·£µå ÀǾàǰ °¡°ÝÀÌ ³ô±â ¶§¹®¿¡ ½ÃÀå ¼ºÀåÀ» ¹æÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ±×·¯³ª, º¸´Ù »õ·Î¿î Ä«Å×°í¸®ÀÇ È£Èí±â¿ë ÀǾàǰ ¿¬±¸°³¹ß, µðÁöÅÐ ±â¼ú Àåºñ¿¡ ´ëÇÑ ÅëÇÕ, »óÀÌÇÑ À¯ÇüÀÇ ÈíÀÔ±â Æ¯¼ºÀ» °áÇÕÇÑ ÇÏÀ̺긮µå ÈíÀԱ⠰³¹ßÀº ȯÀÚ°¡ È¿°úÀûÀÎ Ä¡·á¸¦ º¸´Ù Àú·ÅÇÑ °¡°ÝÀ¸·Î ÀÌ¿ëÇÒ ¼ö ÀÖ°Ô ÇÔÀ¸·Î½á ÀÌ·¯ÇÑ °úÁ¦¸¦ ±Øº¹ÇÒ ¼ö ÀÖ½À´Ï´Ù.

º» Á¶»çÀÇ ÁÖ¿ä Æ¯Â¡

º» º¸°í¼­¿¡¼­´Â ¼¼°èÀÇ È£Èí±â ÈíÀԱ⠽ÃÀåÀ» »ó¼¼ÇÏ°Ô ºÐ¼®ÇÏ¿© 2024³âÀ» ±âÁØ¿¬µµ·Î ÇÑ ¿¹Ãø±â°£(2025-2032³â) ½ÃÀå ±Ô¸ð(10¾ï ´Þ·¯) ¹× ¿¬°£ Æò±Õ ¼ºÀå·ü(CAGR%)À» Á¦°øÇÕ´Ï´Ù.

¶ÇÇÑ ´Ù¾çÇÑ ºÎ¹®¿¡ °ÉÄ£ ÀáÀçÀûÀÎ ¼öÀÍ ±âȸ¸¦ ¹àÈ÷°í ÀÌ ½ÃÀåÀÇ ¸Å·ÂÀûÀÎ ÅõÀÚ Á¦¾È ¸ÅÆ®¸¯½º¸¦ ¼³¸íÇÕ´Ï´Ù.

¶ÇÇÑ ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ±âȸ, ½ÅÁ¦Ç° Ãâ½Ã ¹× ½ÂÀÎ, ½ÃÀå µ¿Çâ, Áö¿ª¿¡ ÀÇÇÑ Àü¸Á, ÁÖ¿ä ±â¾÷ÀÌ Ã¤¿ëÇÏ´Â °æÀï Àü·« µî¿¡ °üÇÑ Áß¿äÇÑ ÀλçÀÌÆ®µµ Á¦°øÇÕ´Ï´Ù.

±â¾÷ ÇÏÀ̶óÀÌÆ®, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÁÖ¿ä ÇÏÀ̶óÀÌÆ®, À繫 ½ÇÀû, Àü·« µîÀÇ ¸Å°³º¯¼ö¸¦ ¹ÙÅÁÀ¸·Î ¼¼°è È£Èí±â ÈíÀԱ⠽ÃÀå¿¡¼­ ÁÖ¿ä ±â¾÷ ÇÁ·ÎÆÄÀÏÀ» Á¦°øÇÕ´Ï´Ù.

º» ¿¬±¸ÀÇ ´ë»óÀÌ µÇ´Â ÁÖ¿ä ±â¾÷Àº GlaxoSmithKline, Merck, Boehringer Ingelheim, AstraZeneca, 3M, Teva Pharmaceutical, Sunovion Pharmaceuticals¸¦ Æ÷ÇÔÇÕ´Ï´Ù.

ÀÌ º¸°í¼­¸¦ ÅëÇØ ÀλçÀÌÆ®´Â ¸¶ÄÉÆÃ ´ã´çÀÚ¿Í ±â¾÷ °æ¿µÁøÀÌ ÇâÈÄ Á¦Ç° Ãâ½Ã, À¯Çü ¾÷±×·¹À̵å, ½ÃÀå È®´ë, ¸¶ÄÉÆÃ Àü¼ú¿¡ ´ëÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç °áÁ¤À» ³»¸± ¼ö ÀÖµµ·Ï ÇÕ´Ï´Ù.

¼¼°èÀÇ È£Èí±â ÈíÀԱ⠽ÃÀå º¸°í¼­´Â ÅõÀÚÀÚ, °ø±Þ¾÷ü, Á¦Ç° Á¦Á¶¾÷ü, À¯Åë¾÷ü, ½Å±Ô Âü°¡ÀÚ, À繫 ºÐ¼®°¡ µî ÀÌ »ê¾÷ÀÇ ´Ù¾çÇÑ ÀÌÇØ°ü°èÀÚ¸¦ Áö¿øÇÕ´Ï´Ù.

ÀÌÇØ°ü°èÀÚ´Â ¼¼°èÀÇ È£Èí±â ÈíÀԱ⠽ÃÀå ºÐ¼®¿¡ »ç¿ëµÇ´Â ´Ù¾çÇÑ Àü·« ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ÀÇ»ç°áÁ¤À» ¿ëÀÌÇÏ°Ô ÇÒ ¼ö ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»çÀÇ ¸ñÀû ¹× ÀüÁ¦Á¶°Ç

Á¦2Àå ½ÃÀå Àü¸Á

Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦ ¹× µ¿Ç⠺м®

Á¦4Àå ¼¼°èÀÇ È£Èí±â ÈíÀԱ⠽ÃÀå : Äڷγª ¹ÙÀÌ·¯½º(COVID-19) ÆÒµ¥¹ÍÀÇ ¿µÇâ

Á¦5Àå ¼¼°èÀÇ È£Èí±â ÈíÀԱ⠽ÃÀå : À¯Çüº°(2020-2032³â)(10¾ï ´Þ·¯)

Á¦6Àå ¼¼°èÀÇ È£Èí±â ÈíÀԱ⠽ÃÀå : Á¦Ç°º°(2020-2032³â)(10¾ï ´Þ·¯)

Á¦7Àå ¼¼°èÀÇ È£Èí±â ÈíÀԱ⠽ÃÀå : ¿ëµµº°(2020-2032³â)(10¾ï ´Þ·¯)

Á¦8Àå ¼¼°èÀÇ È£Èí±â ÈíÀԱ⠽ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº°(2020-2032³â)(10¾ï ´Þ·¯)

Á¦9Àå ¼¼°èÀÇ È£Èí±â ÈíÀԱ⠽ÃÀå : Áö¿ªº°(2020-2032³â)(10¾ï ´Þ·¯)

Á¦10Àå °æÀï ±¸µµ

Á¦11Àå ºÐ¼®°¡ Ãßõ

Á¦12Àå Âü°í¹®Çå ¹× Á¶»ç¹æ¹ý

AJY
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Respiratory Inhalers Market is estimated to be valued at USD 35.10 Bn in 2025 and is expected to reach USD 52.81 Bn by 2032, growing at a compound annual growth rate (CAGR) of 6.0% from 2025 to 2032.

Report Coverage Report Details
Base Year: 2024 Market Size in 2025: USD 35.10 Bn
Historical Data for: 2020 To 2024 Forecast Period: 2025 To 2032
Forecast Period 2025 to 2032 CAGR: 6.00% 2032 Value Projection: USD 52.81 Bn
Figure. Respiratory Inhalers Market Share (%), By Region 2025
Respiratory Inhalers Market - IMG1

Respiratory inhalers are medical devices used for administration of drugs to treat respiratory diseases like asthma and COPD. These help to deliver the required dosage of medication directly to the airways through inhalation. Rising prevalence of respiratory diseases due to environmental factors, growing geriatric population susceptible to such conditions, and increasing awareness about inhaler therapies can drive the market growth. Advancements in inhaler drug delivery technologies, development of smart and digital inhalers, and introduction of combo inhalers with improved efficacy can also drive the market growth. However, high treatment costs and lack of availability in rural regions may hamper its widespread adoption.

Market Dynamics:

Global respiratory inhalers market growth is primarily driven by growing prevalence of respiratory diseases worldwide. Asthma and COPD incidence has increased dramatically in recent decades due to rising pollution levels, changing lifestyle trends, and aging population. As per data from WHO, around 300 million people currently suffer from asthma while over 200 million have COPD. Early diagnosis and availability of effective inhaler therapies have improved the treatment outlook of these conditions. Lack of awareness in low-income nations and high costs of branded drugs in some countries can hamper the market growth. However, ongoing R&D into newer categories of respiratory medicines, integration of digital technology into devices, and development of hybrid inhalers combining attributes of different types of inhalers can overcome these challenges by making effective treatment more affordable and accessible to patients.

Key Features of the Study:

This report provides in-depth analysis of the global respiratory inhalers market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global respiratory inhalers market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include GlaxoSmithKline, Merck, Boehringer Ingelheim, AstraZeneca, 3M, Teva Pharmaceutical, and Sunovion Pharmaceuticals

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

Global respiratory inhalers market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global respiratory inhalers market

Detailed Segmentation-

Table of Contents

1. Research Objectives and Assumptions

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global Respiratory Inhalers Market- Impact of Coronavirus (COVID-19) Pandemic

5. Global Respiratory Inhalers Market, By Type, 2020 - 2032, (USD Bn)

6. Global Respiratory Inhalers Market, By Product, 2020 - 2032, (USD Bn)

7. Global Respiratory Inhalers Market, By Application, 2020 - 2032, (USD Bn)

8. Global Respiratory Inhalers Market, By End User, 2020 - 2032, (USD Bn)

9. Global Respiratory Inhalers Market, By Region, 2020 - 2032, (USD Bn)

10. Competitive Landscape

11. Analyst Recommendations

12. References and Research Methodology

"

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â